Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.



Home / cHL CE Activity Details

cHL CE Activity Details

Incorporating the Latest Therapeutic Advances and Shared Decision Making Into Clinical Practice

Classical Hodgkin lymphoma (cHL) is typically considered to be a curable disease; however, prognosis is poor for the approximately 20% of patients who do not respond to first- or second-line treatments. Fortunately, novel treatment regimens are now available for patients with cHL that may offer improved options for individuals with a poor prognosis. This educational series, which includes 2 audiocasts, presents practical considerations for using these novel treatments. The first audiocast focuses on individualizing treatment, and the second explores best practices for managing treatment-related adverse events.

Learning Objectives

Upon completion, participants should be able to:

  • Tailor treatment regimens for patients with cHL to account for patient-, disease-, and treatment-related factors
  • Compare and contrast the efficacy and safety profiles of available treatments for cHL

Target Audience

This activity is intended for community-based hematologist/oncologists, hematology/oncology nurse practitioners, and hematology/oncology nurses.

Accreditation/Designation Statements

Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
View CE Activity

Our Partner

This activity was developed by Med-IQ in collaboration with the Association of Community Cancer Centers.